With regards general anti-fracture efficacy

in the elderly, risedronate, strontium ranelate, and teriparatide all provide evidence of early risk reduction of vertebral fracture at 1 year with benefits sustained to 3 years for risedronate and strontium ranelate. Alendronate provides evidence of vertebral fracture risk reduction at 3 years only. Anti-fracture efficacy at non-vertebral sites was only provided by strontium ranelate at both time points in women aged ≥80 years. Effect of anti-osteoporosis drugs on fracture healing Whether fracture healing is affected or not by anti-osteoporosis treatment is one of the most important concerns of the orthopedic surgeon, in particular with regard to bisphosphonates that suppress bone-turnover. Animal models of fracture

demonstrate that bisphosphonates delay Ivacaftor mw remodeling of callus, which became larger in size but stronger in structural strength [71, 72]. Raloxifene and estrogen have no major effect on fracture healing [72]. Well-designed randomized clinical OICR-9429 purchase trials in humans to address this important issue are lacking. A small cohort study that compared radiographic fracture healing of the distal radius in 43 patients prescribed bisphosphonate therapy at the time of fracture with 153 selleck compound control subjects revealed that bisphosphonate use was associated with a longer time to radiographic union (55 ± 17 days vs 49 ± 14 days). The differences in healing time were nonetheless small (<1 week) and considered clinically insignificant [73]. The best reassuring piece of clinical evidence in hip fracture patients is provided again by the HORIZON RFT in which zoledronic acid infusion was given within 90 days of hip fracture repair. The incidence of delayed union was

34 (3.2%) in the zoledronic acid group and 29 (2.7%) in the placebo group (risk ratio 1.17; 95% CI 0.72–1.90; P = 0.61) [60]. There was no clinical evidence of impaired facture healing with early administration of a potent bisphosphonate. For bone-forming agents, teriparatide, by virtue of its stimulatory effect on bone formation, has been reported to accelerate remodeling, improve Cytidine deaminase material properties, and enhance fracture healing in animal models [74–76]. Strontium ranelate also significantly increases bone formation, BMD, biomechanical strength, and improves microstructural properties of the callus in a rat model [77]. A direct comparison study using an osteoporotic rat model of fracture healing showed that strontium ranelate enhances callus strength more than teriparatide [78]. Although findings in animal models cannot be extrapolated to humans, there appear to be no suggestions of a negative effect on fracture healing with anti-osteoporosis drug treatment.